462 results on '"Magnussen, C."'
Search Results
2. Safety and efficacy of long-term sodium channel blocker therapy for early rhythm control: the EAST-AFNET 4 trial
- Author
-
Rillig, A, primary, Eckardt, L, additional, Borof, K, additional, Camm, A J, additional, Crijns, J G M, additional, Goette, A, additional, Metzner, A, additional, Schotten, U, additional, Wegscheider, K, additional, Zapf, A, additional, Heidbuchel, H, additional, Willems, S, additional, Schnabel, R, additional, Magnussen, C, additional, and Kirchhof, P, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Newly diagnosed heart failure in patients with atrial fibrillation referred for catheter ablation - identifying patients with arrhythmia-induced cardiomyopathy
- Author
-
Riess, J, primary, Obergassel, J, additional, Nies, M, additional, Rottner, L, additional, Lemoine, M, additional, My, I, additional, Moser, F, additional, Ismaili, D, additional, Schnabel, R B, additional, Magnussen, C, additional, Reissmann, B, additional, Ouyang, F, additional, Metzner, A, additional, Kirchhof, P, additional, and Rillig, A, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Heart rate reduction and outcomes in heart failure outpatients
- Author
-
Memenga, F, primary, Rybczynski, M, additional, Gossling, A, additional, Kirchhof, P, additional, Kondziella, C, additional, Fluschnik, N, additional, Blankenberg, S, additional, Berisha, F, additional, Bernadyn, J, additional, Bremer, W, additional, Becher, M, additional, Magnussen, C, additional, and Knappe, D, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Association of adverse pregnancy outcomes with cardiovascular risk profile in later life - lessons learned from a large prospective population-based cohort-study
- Author
-
Unger, E, primary, Makarova, N, additional, Borof, K, additional, Aarabi, G, additional, Blankenberg, S, additional, Augustin, M, additional, Waldeyer, C, additional, Zengin-Sahm, E, additional, Magnussen, C, additional, Behrendt, C A, additional, Schnabel, R B, additional, and Zyriax, B C, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Longitudinal association between NMR metabolomic lipid profiles and carotid intima-media thickness among youth with severe obesity
- Author
-
Magnussen, C., primary, Saner, C., additional, Burgner, D., additional, Juonala, M., additional, and Sabin, M., additional
- Published
- 2023
- Full Text
- View/download PDF
7. Does Patient Visualisation of Coronary Atherosclerosis Improve Cardiovascular Risk, Lipids, or Blood Pressure in Asymptomatic People at Intermediate Risk?
- Author
-
Whitmore, K., primary, Zhou, Z., additional, Sharman, J., additional, Magnussen, C., additional, Carrington, M., additional, and Marwick, T., additional
- Published
- 2023
- Full Text
- View/download PDF
8. Childhood dyslipidemia and carotid atherosclerotic plaque in adulthood:the Cardiovascular Risk in Young Finns Study
- Author
-
Koskinen, J. S. (Juhani S.), Kytö, V. (Ville), Juonala, M. (Markus), Viikari, J. S. (Jorma S. A.), Nevalainen, J. (Jaakko), Kähönen, M. (Mika), Lehtimäki, T. (Terho), Hutri-Kähönen, N. (Nina), Laitinen, T. P. (Tomi P.), Tossavainen, P. (Päivi), Jokinen, E. (Eero), Magnussen, C. G. (Costan G.), Raitakari, O. T. (Olli T.), Koskinen, J. S. (Juhani S.), Kytö, V. (Ville), Juonala, M. (Markus), Viikari, J. S. (Jorma S. A.), Nevalainen, J. (Jaakko), Kähönen, M. (Mika), Lehtimäki, T. (Terho), Hutri-Kähönen, N. (Nina), Laitinen, T. P. (Tomi P.), Tossavainen, P. (Päivi), Jokinen, E. (Eero), Magnussen, C. G. (Costan G.), and Raitakari, O. T. (Olli T.)
- Abstract
Background: Childhood exposure to dyslipidemia is associated with adult atherosclerosis, but it is unclear whether the long‐term risk associated with dyslipidemia is attenuated on its resolution by adulthood. We aimed to address this question by examining the links between childhood and adult dyslipidemia on carotid atherosclerotic plaques in adulthood. Methods and Results: The Cardiovascular Risk in Young Finns Study is a prospective follow‐up of children that began in 1980. Since then, follow‐up studies have been conducted regularly. In 2001 and 2007, carotid ultrasounds were performed on 2643 participants at the mean age of 36 years to identify carotid plaques and plaque areas. For childhood lipids, we exploited several risk factor measurements to determine the individual cumulative burden for each lipid during childhood. Participants were categorized into the following 4 groups based on their childhood and adult dyslipidemia status: no dyslipidemia (reference), incident, resolved, and persistent. Among individuals with carotid plaque, linear regression models were used to study the association of serum lipids with plaque area. The prevalence of plaque was 3.3% (N=88). In models adjusted for age, sex, and nonlipid cardiovascular risk factors, the relative risk for carotid plaque was 2.34 (95% CI, 0.91–6.00) for incident adult dyslipidemia, 3.00 (95% CI, 1.42–6.34) for dyslipidemia resolved by adulthood, and 5.23 (95% CI, 2.57–10.66) for persistent dyslipidemia. Carotid plaque area correlated with childhood total, low‐density lipoprotein, and non–high‐density lipoprotein cholesterol levels. Conclusions: Childhood dyslipidemia, even if resolved by adulthood, is a risk factor for adult carotid plaque. Furthermore, among individuals with carotid plaque, childhood lipids associate with plaque size. These findings highlight the importance of primordial prevention of dyslipidemia in childhood to reduce atherosclerosis development.
- Published
- 2023
9. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality
- Author
-
Magnussen, C, Ojeda, F, Leong, D, Alegre-Diaz, J, Amouyel, P, Aviles-Santa, L, De Bacquer, D, Ballantyne, C, Bernabé-Ortiz, A, Bobak, M, Brenner, H, Carrillo-Larco, R, de Lemos, J, Dobson, A, Dörr, M, Donfrancesco, C, Drygas, W, Dullaart, R, Engström, G, Ferrario, M, Ferrières, J, de Gaetano, G, Goldbourt, U, Gonzalez, C, Grassi, G, Hodge, A, Hveem, K, Iacoviello, L, Ikram, M, Irazola, V, Jobe, M, Jousilahti, P, Kaleebu, P, Kavousi, M, Kee, F, Khalili, D, Koenig, W, Kontsevaya, A, Kuulasmaa, K, Lackner, K, Leistner, D, Lind, L, Linneberg, A, Lorenz, T, Lyngbakken, M, Malekzadeh, R, Malyutina, S, Mathiesen, E, Melander, O, Metspalu, A, Miranda, J, Moitry, M, Mugisha, J, Nalini, M, Nambi, V, Ninomiya, T, Oppermann, K, D'Orsi, E, Pająk, A, Palmieri, L, Panagiotakos, D, Perianayagam, A, Peters, A, Poustchi, H, Prentice, A, Prescott, E, Risérus, U, Salomaa, V, Sans, S, Sakata, S, Schöttker, B, Schutte, A, Sepanlou, S, Sharma, S, Shaw, J, Simons, L, Söderberg, S, Tamosiunas, A, Thorand, B, Tunstall-Pedoe, H, Twerenbold, R, Vanuzzo, D, Veronesi, G, Waibel, J, Wannamethee, S, Watanabe, M, Wild, P, Yao, Y, Zeng, Y, Ziegler, A, Blankenberg, S, Magnussen, Christina, Ojeda, Francisco M, Leong, Darryl P, Alegre-Diaz, Jesus, Amouyel, Philippe, Aviles-Santa, Larissa, De Bacquer, Dirk, Ballantyne, Christie M, Bernabé-Ortiz, Antonio, Bobak, Martin, Brenner, Hermann, Carrillo-Larco, Rodrigo M, de Lemos, James, Dobson, Annette, Dörr, Marcus, Donfrancesco, Chiara, Drygas, Wojciech, Dullaart, Robin P, Engström, Gunnar, Ferrario, Marco M, Ferrières, Jean, de Gaetano, Giovanni, Goldbourt, Uri, Gonzalez, Clicerio, Grassi, Guido, Hodge, Allison M, Hveem, Kristian, Iacoviello, Licia, Ikram, M Kamran, Irazola, Vilma, Jobe, Modou, Jousilahti, Pekka, Kaleebu, Pontiano, Kavousi, Maryam, Kee, Frank, Khalili, Davood, Koenig, Wolfgang, Kontsevaya, Anna, Kuulasmaa, Kari, Lackner, Karl J, Leistner, David M, Lind, Lars, Linneberg, Allan, Lorenz, Thiess, Lyngbakken, Magnus Nakrem, Malekzadeh, Reza, Malyutina, Sofia, Mathiesen, Ellisiv B, Melander, Olle, Metspalu, Andres, Miranda, J Jaime, Moitry, Marie, Mugisha, Joseph, Nalini, Mahdi, Nambi, Vijay, Ninomiya, Toshiharu, Oppermann, Karen, d'Orsi, Eleonora, Pająk, Andrzej, Palmieri, Luigi, Panagiotakos, Demosthenes, Perianayagam, Arokiasamy, Peters, Annette, Poustchi, Hossein, Prentice, Andrew M, Prescott, Eva, Risérus, Ulf, Salomaa, Veikko, Sans, Susana, Sakata, Satoko, Schöttker, Ben, Schutte, Aletta E, Sepanlou, Sadaf G, Sharma, Sanjib Kumar, Shaw, Jonathan E, Simons, Leon A, Söderberg, Stefan, Tamosiunas, Abdonas, Thorand, Barbara, Tunstall-Pedoe, Hugh, Twerenbold, Raphael, Vanuzzo, Diego, Veronesi, Giovanni, Waibel, Julia, Wannamethee, S Goya, Watanabe, Masafumi, Wild, Philipp S, Yao, Yao, Zeng, Yi, Ziegler, Andreas, Blankenberg, Stefan, Magnussen, C, Ojeda, F, Leong, D, Alegre-Diaz, J, Amouyel, P, Aviles-Santa, L, De Bacquer, D, Ballantyne, C, Bernabé-Ortiz, A, Bobak, M, Brenner, H, Carrillo-Larco, R, de Lemos, J, Dobson, A, Dörr, M, Donfrancesco, C, Drygas, W, Dullaart, R, Engström, G, Ferrario, M, Ferrières, J, de Gaetano, G, Goldbourt, U, Gonzalez, C, Grassi, G, Hodge, A, Hveem, K, Iacoviello, L, Ikram, M, Irazola, V, Jobe, M, Jousilahti, P, Kaleebu, P, Kavousi, M, Kee, F, Khalili, D, Koenig, W, Kontsevaya, A, Kuulasmaa, K, Lackner, K, Leistner, D, Lind, L, Linneberg, A, Lorenz, T, Lyngbakken, M, Malekzadeh, R, Malyutina, S, Mathiesen, E, Melander, O, Metspalu, A, Miranda, J, Moitry, M, Mugisha, J, Nalini, M, Nambi, V, Ninomiya, T, Oppermann, K, D'Orsi, E, Pająk, A, Palmieri, L, Panagiotakos, D, Perianayagam, A, Peters, A, Poustchi, H, Prentice, A, Prescott, E, Risérus, U, Salomaa, V, Sans, S, Sakata, S, Schöttker, B, Schutte, A, Sepanlou, S, Sharma, S, Shaw, J, Simons, L, Söderberg, S, Tamosiunas, A, Thorand, B, Tunstall-Pedoe, H, Twerenbold, R, Vanuzzo, D, Veronesi, G, Waibel, J, Wannamethee, S, Watanabe, M, Wild, P, Yao, Y, Zeng, Y, Ziegler, A, Blankenberg, S, Magnussen, Christina, Ojeda, Francisco M, Leong, Darryl P, Alegre-Diaz, Jesus, Amouyel, Philippe, Aviles-Santa, Larissa, De Bacquer, Dirk, Ballantyne, Christie M, Bernabé-Ortiz, Antonio, Bobak, Martin, Brenner, Hermann, Carrillo-Larco, Rodrigo M, de Lemos, James, Dobson, Annette, Dörr, Marcus, Donfrancesco, Chiara, Drygas, Wojciech, Dullaart, Robin P, Engström, Gunnar, Ferrario, Marco M, Ferrières, Jean, de Gaetano, Giovanni, Goldbourt, Uri, Gonzalez, Clicerio, Grassi, Guido, Hodge, Allison M, Hveem, Kristian, Iacoviello, Licia, Ikram, M Kamran, Irazola, Vilma, Jobe, Modou, Jousilahti, Pekka, Kaleebu, Pontiano, Kavousi, Maryam, Kee, Frank, Khalili, Davood, Koenig, Wolfgang, Kontsevaya, Anna, Kuulasmaa, Kari, Lackner, Karl J, Leistner, David M, Lind, Lars, Linneberg, Allan, Lorenz, Thiess, Lyngbakken, Magnus Nakrem, Malekzadeh, Reza, Malyutina, Sofia, Mathiesen, Ellisiv B, Melander, Olle, Metspalu, Andres, Miranda, J Jaime, Moitry, Marie, Mugisha, Joseph, Nalini, Mahdi, Nambi, Vijay, Ninomiya, Toshiharu, Oppermann, Karen, d'Orsi, Eleonora, Pająk, Andrzej, Palmieri, Luigi, Panagiotakos, Demosthenes, Perianayagam, Arokiasamy, Peters, Annette, Poustchi, Hossein, Prentice, Andrew M, Prescott, Eva, Risérus, Ulf, Salomaa, Veikko, Sans, Susana, Sakata, Satoko, Schöttker, Ben, Schutte, Aletta E, Sepanlou, Sadaf G, Sharma, Sanjib Kumar, Shaw, Jonathan E, Simons, Leon A, Söderberg, Stefan, Tamosiunas, Abdonas, Thorand, Barbara, Tunstall-Pedoe, Hugh, Twerenbold, Raphael, Vanuzzo, Diego, Veronesi, Giovanni, Waibel, Julia, Wannamethee, S Goya, Watanabe, Masafumi, Wild, Philipp S, Yao, Yao, Zeng, Yi, Ziegler, Andreas, and Blankenberg, Stefan
- Abstract
BACKGROUND: Five modifiable risk factors are associated with cardiovascular disease and death from any cause. Studies using individual-level data to evaluate the regional and sex-specific prevalence of the risk factors and their effect on these outcomes are lacking. METHODS: We pooled and harmonized individual-level data from 112 cohort studies conducted in 34 countries and 8 geographic regions participating in the Global Cardiovascular Risk Consortium. We examined associations between the risk factors (body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes) and incident cardiovascular disease and death from any cause using Cox regression analyses, stratified according to geographic region, age, and sex. Population-attributable fractions were estimated for the 10-year incidence of cardiovascular disease and 10-year all-cause mortality. RESULTS: Among 1,518,028 participants (54.1% of whom were women) with a median age of 54.4 years, regional variations in the prevalence of the five modifiable risk factors were noted. Incident cardiovascular disease occurred in 80,596 participants during a median follow-up of 7.3 years (maximum, 47.3), and 177,369 participants died during a median follow-up of 8.7 years (maximum, 47.6). For all five risk factors combined, the aggregate global population-attributable fraction of the 10-year incidence of cardiovascular disease was 57.2% (95% confidence interval [CI], 52.4 to 62.1) among women and 52.6% (95% CI, 49.0 to 56.1) among men, and the corresponding values for 10-year all-cause mortality were 22.2% (95% CI, 16.8 to 27.5) and 19.1% (95% CI, 14.6 to 23.6). CONCLUSIONS: Harmonized individual-level data from a global cohort showed that 57.2% and 52.6% of cases of incident cardiovascular disease among women and men, respectively, and 22.2% and 19.1% of deaths from any cause among women and men, respectively, may be attributable to five modifiable risk factors. (Funded by the
- Published
- 2023
10. Childhood fitness reduces the long-term cardiometabolic risks associated with childhood obesity
- Author
-
Schmidt, M D, Magnussen, C G, Rees, E, Dwyer, T, and Venn, A J
- Published
- 2016
- Full Text
- View/download PDF
11. Cumulative dyslipidaemia from mid-adolescence through young adulthood with carotid intima-media thickness progression: a 9-year longitudinal study
- Author
-
Agbaje, A O, primary, Lloyd-Jones, D M, additional, Magnussen, C G, additional, and Tuomainen, T P, additional
- Published
- 2022
- Full Text
- View/download PDF
12. Simulated intervention and optimal timing for attenuating dyslipidaemia-related atherosclerotic progression in the young: a temporal inverse allocation analysis of the ALSPAC cohort
- Author
-
Agbaje, A O, primary, Lloyd-Jones, D M, additional, Magnussen, C G, additional, and Tuomainen, T P, additional
- Published
- 2022
- Full Text
- View/download PDF
13. Longitudinal associations of cumulative dyslipidaemia from mid-adolescence through young adulthood with arterial stiffness progression: the ALSPAC study
- Author
-
Agbaje, A O, primary, Lloyd-Jones, D M, additional, Magnussen, C G, additional, and Tuomainen, T P, additional
- Published
- 2022
- Full Text
- View/download PDF
14. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
- Author
-
Hageman, S., Pennells, L., Ojeda, F., Kaptoge, S., Kuulasmaa, K., Vries, T. de, Xu, Z., Kee, F., Chung, R., Wood, A., McEvoy, J.W., Veronesi, G., Bolton, T., Dendale, P., Ference, B.A., Halle, M., Timmis, A., Vardas, P., Danesh, J., Graham, I., Salomaa, V., Visseren, F., Bacquer, D. de, Blankenberg, S., Dorresteijn, J., Angelantonio, E. di, Achenbach, S., Aleksandrova, K., Amiano, P., Amouyel, P., Andersson, J., Bakker, S.J.L., Costa, R.B.D., Beulens, J.W.J., Blaha, M., Bobak, M., Boer, J.M.A., Bonet, C., Bonnet, F., Boutron-Ruault, M.C., Braaten, T., Brenner, H., Brunner, F., Brunner, E.J., Brunstrom, M., Buring, J., Butterworth, A.S., Capkova, N., Cesana, G., Chrysohoou, C., Colorado-Yohar, S., Cook, N.R., Cooper, C., Dahm, C.C., Davidson, K., Dennison, E., Castelnuovo, A. di, Donfrancesco, C., Dorr, M., Dorynska, A., Eliasson, M., Engstrom, G., Ferrari, P., Ferrario, M., Ford, I., Fu, M., Gansevoort, R.T., Giampaoli, S., Gillum, R.F., Camara, A.G. de la, Grassi, G., Hansson, P.O., Huculeci, R., Hveem, K., Iacoviello, L., Ikram, M.K., Jorgensen, T., Joseph, B., Jousilahti, P., Jukema, J.W., Kaaks, R., Katzke, V., Kavousi, M., Kiechl, S., Klotsche, J., Konig, W., Kronmal, R.A., Kubinova, R., Kucharska-Newton, A., Lall, K., Lehmann, N., Leistner, D., Linneberg, A., Pablos, D.L., Lorenz, T., Lu, W.T., Luksiene, D., Lyngbakken, M., Magnussen, C., Malyutina, S., Ibanez, A.M., Masala, G., Mathiesen, E.B., Matsushita, K., Meade, T.W., Melander, O., Meyer, H.E., Moons, K.G.M., Moreno-Iribas, C., Muller, D., Munzel, T., Nikitin, Y., Nordestgaard, B.G., Omland, T., Onland, C., Overvad, K., Packard, C., Pajak, A., Palmieri, L., Panagiotakos, D., Panico, S., Perez-Cornago, A., Peters, A., Pietila, A., Pikhart, H., Psaty, B.M., Quarti-Trevano, F., Garcia, J.R.Q., Riboli, E., Ridker, P.M., Rodriguez, B., Rodriguez-Barranco, M., Rosengren, A., Roussel, R., Sacerdote, C., Sans, S., Sattar, N., Schiborn, C., Schmidt, B., Schottker, B., Schulze, M., Schwartz, J.E., Selmer, R.M., Shea, S., Shipley, M.J., Sieri, S., Soderberg, S., Sofat, R., Tamosiunas, A., Thorand, B., Tillmann, T., Tjonneland, A., Tong, T.Y.N., Trichopoulou, A., Tumino, R., Tunstall-Pedoe, H., Tybjaerg-Hansen, A., Tzoulaki, J., Heijden, A. van der, Schouw, Y.T. van der, Verschuren, W.M.M., Volzke, H., Waldeyer, C., Wareham, N.J., Weiderpass, E., Weidinger, F., Wild, P., Willeit, J., Willeit, P., Wilsgaard, T., Woodward, M., Zeller, T., Zhang, D.D., Zhou, B., SCORE2 Working Grp, ESC Cardiovasc Risk Collaboration, collaboration, SCORE2 working group and ESC Cardiovascular risk, Groningen Institute for Organ Transplantation (GIOT), Groningen Kidney Center (GKC), Cardiovascular Centre (CVC), Epidemiology, Neurology, Achenbach, S, Aleksandrova, K, Amiano, P, San Sebastian, D, Amouyel, P, Andersson, J, Bakker, S, Da Providencia Costa, R, Beulens, J, Blaha, M, Bobak, M, Boer, J, Bonet, C, Bonnet, F, Boutron-Ruault, M, Braaten, T, Brenner, H, Brunner, F, Brunner, E, Brunström, M, Buring, J, Butterworth, A, Capkova, N, Cesana, G, Chrysohoou, C, Colorado-Yohar, S, Cook, N, Cooper, C, Dahm, C, Davidson, K, Dennison, E, Di Castelnuovo, A, Donfrancesco, C, Dörr, M, Doryńska, A, Eliasson, M, Engström, G, Ferrari, P, Ferrario, M, Ford, I, Fu, M, Gansevoort, R, Giampaoli, S, Gillum, R, Gómez de la Cámara, A, Grassi, G, Hansson, P, Huculeci, R, Hveem, K, Iacoviello, L, Ikram, M, Jørgensen, T, Joseph, B, Jousilahti, P, Wouter Jukema, J, Kaaks, R, Katzke, V, Kavousi, M, Kiechl, S, Klotsche, J, König, W, Kronmal, R, Kubinova, R, Kucharska-Newton, A, Läll, K, Lehmann, N, Leistner, D, Linneberg, A, Pablos, D, Lorenz, T, Lu, W, Luksiene, D, Lyngbakken, M, Magnussen, C, Malyutina, S, Ibañez, A, Masala, G, Mathiesen, E, Matsushita, K, Meade, T, Melander, O, Meyer, H, Moons, K, Moreno-Iribas, C, Muller, D, Münzel, T, Nikitin, Y, Nordestgaard, B, Omland, T, Onland, C, Overvad, K, Packard, C, Pająk, A, Palmieri, L, Panagiotakos, D, Panico, S, Perez-Cornago, A, Peters, A, Pietilä, A, Pikhart, H, Psaty, B, Quarti-Trevano, F, Garcia, J, Riboli, E, Ridker, P, Rodriguez, B, Rodriguez-Barranco, M, Rosengren, A, Roussel, R, Sacerdote, C, S, S, Sattar, N, Schiborn, C, Schmidt, B, Schöttker, B, Schulze, M, Schwartz, J, Selmer, R, Shea, S, Shipley, M, Sieri, S, Söderberg, S, Sofat, R, Tamosiunas, A, Thorand, B, Tillmann, T, Tjønneland, A, Tong, T, Trichopoulou, A, Tumino, R, Tunstall-Pedoe, H, Tybjaerg-Hansen, A, Tzoulaki, J, van der Heijden, A, van der Schouw, Y, Verschuren, W, Völzke, H, Waldeyer, C, Wareham, N, Weiderpass, E, Weidinger, F, Wild, P, Willeit, J, Willeit, P, Wilsgaard, T, Woodward, M, Zeller, T, Zhang, D, Zhou, B, and Apollo - University of Cambridge Repository
- Subjects
Male ,Cardiology ,RATIONALE ,Blood Pressure ,Disease ,030204 cardiovascular system & hematology ,PROFILE ,ACUTE CORONARY EVENTS ,VALIDATION ,Europe/epidemiology ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,DESIGN ,Clinical Research ,Risk Factors ,Diabetes mellitus ,medicine ,PARTICIPANTS ,Humans ,030212 general & internal medicine ,Risk factor ,Aged ,Primary prevention ,business.industry ,10-year CVD risk ,Incidence (epidemiology) ,Cardiovascular Diseases/epidemiology ,Risk Prediction ,Cardiovascular Disease ,Primary Prevention ,10-year Cvd Risk ,External validation ,PRIMARY-CARE ,Middle Aged ,medicine.disease ,Cardiovascular disease ,Risk prediction ,3. Good health ,Europe ,Prediction algorithms ,Blood pressure ,Cardiovascular Diseases ,Smoking status ,Female ,Cardiology and Cardiovascular Medicine ,business ,Algorithms ,Demography - Abstract
Aims The aim of this study was to develop, validate, and illustrate an updated prediction model (SCORE2) to estimate 10-year fatal and non-fatal cardiovascular disease (CVD) risk in individuals without previous CVD or diabetes aged 40-69 years in Europe.Methods and results We derived risk prediction models using individual-participant data from 45 cohorts in 13 countries (677 684 individuals, 30 121 CVD events). We used sex-specific and competing risk-adjusted models, including age, smoking status, systolic blood pressure, and total- and HDL-cholesterol. We defined four risk regions in Europe according to country-specific CVD mortality, recalibrating models to each region using expected incidences and risk factor distributions. Region-specific incidence was estimated using CVD mortality and incidence data on 10 776 466 individuals. For external validation, we analysed data from 25 additional cohorts in 15 European countries (1 133 181 individuals, 43 492 CVD events). After applying the derived risk prediction models to external validation cohorts, C-indices ranged from 0.67 (0.65-0.68) to 0.81 (0.76-0.86). Predicted CVD risk varied several-fold across European regions. For example, the estimated 10-year CVD risk for a 50-year-old smoker, with a systolic blood pressure of 140 mmHg, total cholesterol of 5.5 mmol/L, and HDL-cholesterol of 1.3 mmol/L, ranged from 5.9% for men in low- risk countries to 14.0% for men in very high-risk countries, and from 4.2% for women in low-risk countries to 13.7% for women in very high-risk countries.Conclusion SCORE2-a new algorithm derived, calibrated, and validated to predict 10-year risk of first-onset CVD in European populations-enhances the identification of individuals at higher risk of developing CVD across Europe. Acknowledgements We thank investigators and participants of the several studies that contributed data to the Emerging Risk Factors Collaboration (ERFC). This research has been conducted using the UK Biobank Resource under Application Number 26865. Data from the Clinical Practice Research Datalink (CPRD) were obtained under licence from the UK Medicines and Healthcare products Regulatory Agency (protocol 162RMn2). CPRD uses data provided by patients and collected by the NHS as part of their care and support. We thank all EPIC participants and staff for their contribution to the study, the laboratory teams at the Medical Research Council Epidemiology Unit for sample management and Cambridge Genomic Services for genotyping, Sarah Spackman for data management and the team at the EPIC-CVD Coordinating Centre for study co-ordination and administration. Funding The ERFC co-ordinating centre was underpinned by programme grants from the British Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946), BHF Centre of Research Excellence (RE/18/1/34212), the UK Medical Research Council (MR/L003120/1), and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC1215-20014), with project-specific support received from the UK NIHR [*], British United Provident Association UK Foundation and an unrestricted educational grant from GlaxoSmithKline. A variety of funding sources have supported recruitment, follow-up, and laboratory measurements in the studies contributing data to the ERFC, which are listed on the ERFC website (www.phpc.cam.ac.uk/ceu/erfc/list-of-studies). *The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, and Wellcome. The MORGAM Project has received funding from EU projects MORGAM (Biomed BMH4-CT98-3183), GenomEUtwin (FP5, QLG2-CT-2002-01254), ENGAGE (FP7, HEALTH-F4-2007-201413),CHANCES (FP7, HEALTH-F3-2010-242244), BiomarCaRE (FP7,HEALTH-F2-2011-278913), euCanSHare (Horizon 2020, No. 825903) and AFFECT-EU (Horizon 2020, No. 847770); and Medical Research Council, London (G0601463, No. 80983: Biomarkers in the MORGAM Populations). This has supported central coordination, workshops and part of the activities of the MORGAM Data Centre, the MORGAM Laboratories and the MORGAM Participating Centres EPIC-CVD was funded by the European Research Council (268834), and the European Commission Framework Programme 7 (HEALTH-F2-2012-279233). This work was supported by the Estonian Research Council grant PUTs (PRG687, PUT1660, PUT1665, PRG184), by European Union through the European Regional Development Fund project no. MOBERA5 (Norface Network project no 462.16.107), by the Green ICT programme under Norway Grants 2014 – 2021 (grant number EU53928), by the European Union through Horizon 2020 grant no. 810645 and through the European Regional Development Fund (Project No. 2014-2020.4.01.16-0125) and by the PRECISE4Q consortium. PRECISE4Q project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant agreement 777107. This work was partly funded through the CoMorMent project. CoMorMent has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant agreement 847776. The KORA study was initiated and financed by the Helmholtz Zentrum Mu¨nchen—German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. The KORA study was supported by a research grant from the Virtual Institute of Diabetes Research (Helmholtz Zentrum Mu¨nchen), the Clinical Cooperation Group Diabetes between Ludwig-Maximilians-Universita¨t Mu¨nchen and Helmholtz Zentrum Mu¨nchen, and by the German Diabetes Center (DDZ). The HAPIEE project, Institute, was supported by grants from the Wellcome Trust (064947/Z/01/Z; WT081081) and US National Institute on Aging (1R01 and AG23522). The co-ordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Ge´ne´rale de l’Education Nationale, Institut National de la Sante´ et de la Recherche Me´dicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch 2448 SCORE2 working group and ESC Cardiovascular Risk Collaboration Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucı´a, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology—ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Ska˚ne and Va¨sterbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom)
- Published
- 2021
- Full Text
- View/download PDF
15. Longitudinal investigation of adenovirus 36 seropositivity and human obesity: the Cardiovascular Risk in Young Finns Study
- Author
-
Sabin, M A, Burgner, D, Atkinson, R L, Pei-Lun Lee, Z, Magnussen, C G, Cheung, M, Kähönen, M, Lehtimäki, T, Jokinen, E, Laitinen, T, Hutri-Kähönen, N, Viikari, J S A, Juonala, M, and Raitakari, O T
- Published
- 2015
- Full Text
- View/download PDF
16. Is Personalisation of Cardiovascular Risk a Superior Approach to Engage Primary Care in the Continuation of Statin Use Over Conventional Risk Information?
- Author
-
Whitmore, K., Zhou, Z., Magnussen, C., Marwick, T., and Carrington, M.
- Published
- 2024
- Full Text
- View/download PDF
17. Symptom burden, psychosocial distress and palliative care needs in heart failure – A cross-sectional explorative pilot study
- Author
-
Strangl, F., primary, Ischanow, E., additional, Ullrich, A., additional, Oechsle, K., additional, Fluschnik, N., additional, Magnussen, C., additional, Knappe, D., additional, Grahn, H., additional, Blankenberg, S., additional, Bokemeyer, C., additional, Kirchhof, P., additional, and Rybczynski, M., additional
- Published
- 2022
- Full Text
- View/download PDF
18. Impact of Treatment Strategies and Hemodynamics on Kidney Function After Heart Transplantation
- Author
-
Wagner, T., primary, Budelmann, T., additional, Volgmann, C., additional, Bernhardt, A., additional, Knappe, D., additional, Magnussen, C., additional, Reichenspurner, H., additional, Kirchhof, P., additional, and Grahn, H., additional
- Published
- 2022
- Full Text
- View/download PDF
19. Sex Differences in Clinical Characteristics and Outcomes in Patients Undergoing Heart Transplantation
- Author
-
Kondziella, C., primary, Fluschnik, N., additional, Weimann, J., additional, Bernhard, A.M., additional, Schrage, B., additional, Blankenberg, S., additional, Reichenspurner, H., additional, Kirchhof, P., additional, Schnabel, R.B., additional, and Magnussen, C., additional
- Published
- 2022
- Full Text
- View/download PDF
20. Predictors of Humoral Response to COVID-19 Vaccination in Heart Transplant Recipients
- Author
-
Memenga, F., primary, Kueppers, S., additional, Borof, K., additional, Knappe, D., additional, Blankenberg, S., additional, Barten, M.J., additional, Reichenspurner, H., additional, Kirchhof, P., additional, Magnussen, C., additional, and Rybczynski, M., additional
- Published
- 2022
- Full Text
- View/download PDF
21. Type 2 diabetes, retinal small vessel disease and brain atrophy: OR01
- Author
-
Moran, C, Tapp, R J, Hughes, A D, Magnussen, C G, Blizzard, L, Phan, T G, Beare, R, Witt, N, Venn, A, Müench, G, Amaratunge, B C, and Srikanth, V
- Published
- 2016
22. Low birth weight predicts impaired cardiac structure and function in mid-adulthood
- Author
-
Huynh, Q, primary, Magnussen, C, additional, Venn, A, additional, and Marwick, T, additional
- Published
- 2021
- Full Text
- View/download PDF
23. Non-invasive risk prediction based on right ventricular function in patients with pulmonary arterial hypertension
- Author
-
Qaderi, V, primary, Weimann, J, additional, Harbaum, L, additional, Schrage, B, additional, Knappe, D, additional, Sinning, C, additional, Schnabel, R, additional, Blankenberg, S, additional, Kirchhof, P, additional, Klose, H, additional, and Magnussen, C, additional
- Published
- 2021
- Full Text
- View/download PDF
24. Prediction of future atherosclerosis in 13 years from young asymptomatic adults
- Author
-
Huynh, Q, primary, Magnussen, C, additional, Venn, A, additional, Dwyer, T, additional, and Marwick, T, additional
- Published
- 2021
- Full Text
- View/download PDF
25. Exposure to Parental Smoking in Childhood Is Associated with Increased Carotid Intima-Media Thickness in Young Adults: Evidence from Two Prospective Cohort Studies in Australia and Finland: 2
- Author
-
Gall, S., Huynh, Q. L., Magnussen, C. G., Juonala, M., Viikari, J. S.A., Kähönen, M., Dwyer, T., Raitakari, O. T., and Venn, A.
- Published
- 2014
26. Childhood Exposure to Parental Smoking and Midlife Cognitive Function The Young Finns Study
- Author
-
Rovio, S. P. (Suvi P.), Pihlman, J. (Jukka), Pahkala, K. (Katja), Juonala, M. (Markus), Magnussen, C. G. (Costan G.), Pitkänen, N. (Niina), Ahola-Olli, A. (Ari), Salo, P. (Pia), Kähönen, M. (Mika), Hutri-Kähönen, N. (Nina), Lehtimäki, T. (Terho), Jokinen, E. (Eero), Laitinen, T. (Tomi), Taittonen, L. (Leena), Tossavainen, P. (Päivi), Viikari, J. S. (Jorma S. A.), Raitakari, O. T. (Olli T.), Institute for Molecular Medicine Finland, Genomics of Neurological and Neuropsychiatric Disorders, University of Helsinki, HUS Children and Adolescents, Lastentautien yksikkö, and Children's Hospital
- Subjects
SECONDHAND SMOKE ,parental smoking ,passive smoking ,NICOTINE EXPOSURE ,Cambridge Neuropsychological Test Automated Battery ,ADULTHOOD ,PERFORMANCE ,3142 Public health care science, environmental and occupational health ,COTININE ,AGE ,CIGARETTE-SMOKE ,SELF-REPORTED SMOKING ,CARDIOVASCULAR RISK-FACTORS ,OXIDATIVE STRESS ,tobacco smoke ,cognitive function ,secondhand smoke - Abstract
We studied whether exposure to parental smoking in childhood/adolescence is associated with midlife cognitive function, leveraging data from the Cardiovascular Risk in Young Finns Study. A population-based cohort of 3,596 children/adolescents aged 3–18 years was followed between 1980 and 2011. In 2011, cognitive testing was performed on 2,026 participants aged 34–49 years using computerized testing. Measures of secondhand smoke exposure in childhood/adolescence consisted of parental self-reports of smoking and participants’ serum cotinine levels. Participants were classified into 3 exposure groups: 1) no exposure (nonsmoking parents, cotinine
- Published
- 2020
27. Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD)
- Author
-
Cuthbertson, D. J. (Daniel J.), Koskinen, J. (Juha), Brown, E. (Emily), Magnussen, C. G. (Costan G.), Hutri-Kähönen, N. (Nina), Sabin, M. (Matthew), Tossavainen, P. (Päivi), Jokinen, E. (Eero), Laitinen, T. (Tomi), Viikari, J. (Jorma), Raitakari, O. T. (Olli T.), Juonalaj, M. (Markus), Cuthbertson, D. J. (Daniel J.), Koskinen, J. (Juha), Brown, E. (Emily), Magnussen, C. G. (Costan G.), Hutri-Kähönen, N. (Nina), Sabin, M. (Matthew), Tossavainen, P. (Päivi), Jokinen, E. (Eero), Laitinen, T. (Tomi), Viikari, J. (Jorma), Raitakari, O. T. (Olli T.), and Juonalaj, M. (Markus)
- Abstract
Aims: To investigate the association between overweight/obesity and fatty liver index (FLI) on the odds of incident prediabetes/type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) in 2020 participants after 10 years follow up. Methods: At baseline (in 2001) 2020 participants, males and females, aged 24–39 years, were stratified according to body mass index (BMI), normal weight (<25 kg/m²), overweight (≥25–<30 kg/m²), or obese (≥30 kg/m²) and FLI (as high FLI ≥60 or low FLI <60). We examined the incidence of prediabetes/type 2 diabetes and NAFLD (ultrasound assessed) over 10 years to 2011 to determine the relative impact of FLI and BMI. Results: 514 and 52 individuals developed prediabetes and type 2 diabetes during follow-up. Such individuals were older, with higher BMI, serum glucose, insulin, alanine aminotransferase (ALT) and triglyceride (TG) concentrations than those who did not develop prediabetes or type 2 diabetes (n = 1454). The additional presence of high FLI significantly increased the risk of developing prediabetes and type 2 diabetes above the risk of being overweight/obese. Compared with normal weight, low FLI participants, the odds of prediabetes were ∼2-fold higher and the odds of type 2 diabetes were 9–10-fold higher respectively in the overweight/obese, high FLI group. No difference was observed between normal weight, low FLI and overweight/obese and low FLI groups. Conclusions: An increased FLI significantly increases the odds of incident prediabetes, type 2 diabetes and NAFLD in individuals with overweight/obese highlighting the contributory role of liver fat accumulation in the pathophysiology of prediabetes/type 2 diabetes.
- Published
- 2021
28. Association between number of siblings and cardiovascular risk factors in childhood and in adulthood:the Cardiovascular Risk in Young Finns Study
- Author
-
Pihlman, J. (Jukka), Magnussen, C. G. (Costan G.), Rovio, S. P. (Suvi P.), Pahkala, K. (Katja), Jokinen, E. (Eero), Laitinen, T. P. (Tomi P.), Hutri-Kähönen, N. (Nina), Tossavainen, P. (Päivi), Taittonen, L. (Leena), Kähönen, M. (Mika), Viikari, J. S. (Jorma S. A.), Raitakari, O. T. (Olli T.), Juonala, M. (Markus), Nuotio, J. (Joel), Pihlman, J. (Jukka), Magnussen, C. G. (Costan G.), Rovio, S. P. (Suvi P.), Pahkala, K. (Katja), Jokinen, E. (Eero), Laitinen, T. P. (Tomi P.), Hutri-Kähönen, N. (Nina), Tossavainen, P. (Päivi), Taittonen, L. (Leena), Kähönen, M. (Mika), Viikari, J. S. (Jorma S. A.), Raitakari, O. T. (Olli T.), Juonala, M. (Markus), and Nuotio, J. (Joel)
- Abstract
Objective: To determine the association of number of siblings on cardiovascular risk factors in childhood and in adulthood. Study design: In total, 3554 participants (51% female) from the Cardiovascular Risk in Young Finns Study with cardiovascular disease risk factor data at baseline 1980 (age 3–18 years) and 2491 participants with longitudinal risk factor data at the 2011 follow-up. Participants were categorized by number of siblings at baseline (0, 1, or more than 1). Risk factors (body mass index, physical activity, hypertension, dyslipidemia, and overweight, and metabolic syndrome) in childhood and in adulthood were used as outcomes. Analyses were adjusted for age and sex. Results: In childhood, participants without siblings had higher body mass index (18.2 kg/m², 95% CI 18.0-18.3) than those with 1 sibling (17.9 kg/m², 95% CI 17.8-18.0) or more than 1 sibling (17.8 kg/m², 95% CI 17.7-17.9). Childhood physical activity index was lower among participants without siblings (SD -0.08, 95% CI -0.16-0.00) compared with participants with 1 sibling (SD 0.06, 95%CI 0.01-0.11) or more than 1 sibling (SD -0.02, 95% CI -0.07-0.03). OR for adulthood hypertension was lower among participants with 1 sibling (OR 0.73, 95% CI 0.54-0.98) and more than 1 sibling (OR 0.71, 95% CI 0.52-0.97) compared with participants with no siblings. OR for obesity was lower among participants with 1 sibling (OR 0.72, 95% CI 0.54-0.95) and more than 1 sibling (OR 0.75, 95% CI 0.56-1.01) compared with those with no siblings. Conclusions: Children without siblings had poorer cardiovascular risk factor levels in childhood and in adulthood. The number of siblings could help identify individuals at increased risk that might benefit from early intervention.
- Published
- 2021
29. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
- Author
-
Achenbach, S, Aleksandrova, K, Amiano, P, San Sebastian, D, Amouyel, P, Andersson, J, Bakker, S, Da Providencia Costa, R, Beulens, J, Blaha, M, Bobak, M, Boer, J, Bonet, C, Bonnet, F, Boutron-Ruault, M, Braaten, T, Brenner, H, Brunner, F, Brunner, E, Brunström, M, Buring, J, Butterworth, A, Capkova, N, Cesana, G, Chrysohoou, C, Colorado-Yohar, S, Cook, N, Cooper, C, Dahm, C, Davidson, K, Dennison, E, Di Castelnuovo, A, Donfrancesco, C, Dörr, M, Doryńska, A, Eliasson, M, Engström, G, Ferrari, P, Ferrario, M, Ford, I, Fu, M, Gansevoort, R, Giampaoli, S, Gillum, R, Gómez de la Cámara, A, Grassi, G, Hansson, P, Huculeci, R, Hveem, K, Iacoviello, L, Ikram, M, Jørgensen, T, Joseph, B, Jousilahti, P, Wouter Jukema, J, Kaaks, R, Katzke, V, Kavousi, M, Kiechl, S, Klotsche, J, König, W, Kronmal, R, Kubinova, R, Kucharska-Newton, A, Läll, K, Lehmann, N, Leistner, D, Linneberg, A, Pablos, D, Lorenz, T, Lu, W, Luksiene, D, Lyngbakken, M, Magnussen, C, Malyutina, S, Ibañez, A, Masala, G, Mathiesen, E, Matsushita, K, Meade, T, Melander, O, Meyer, H, Moons, K, Moreno-Iribas, C, Muller, D, Münzel, T, Nikitin, Y, Nordestgaard, B, Omland, T, Onland, C, Overvad, K, Packard, C, Pająk, A, Palmieri, L, Panagiotakos, D, Panico, S, Perez-Cornago, A, Peters, A, Pietilä, A, Pikhart, H, Psaty, B, Quarti-Trevano, F, Garcia, J, Riboli, E, Ridker, P, Rodriguez, B, Rodriguez-Barranco, M, Rosengren, A, Roussel, R, Sacerdote, C, S, S, Sattar, N, Schiborn, C, Schmidt, B, Schöttker, B, Schulze, M, Schwartz, J, Selmer, R, Shea, S, Shipley, M, Sieri, S, Söderberg, S, Sofat, R, Tamosiunas, A, Thorand, B, Tillmann, T, Tjønneland, A, Tong, T, Trichopoulou, A, Tumino, R, Tunstall-Pedoe, H, Tybjaerg-Hansen, A, Tzoulaki, J, van der Heijden, A, van der Schouw, Y, Verschuren, W, Völzke, H, Waldeyer, C, Wareham, N, Weiderpass, E, Weidinger, F, Wild, P, Willeit, J, Willeit, P, Wilsgaard, T, Woodward, M, Zeller, T, Zhang, D, Zhou, B, Bakker, SJL, Da Providencia Costa, RB, Beulens, JWJ, Boer, JMA, Boutron-Ruault, MC, Brunner, EJ, Butterworth, AS, Cook, NR, Dahm, CC, Gansevoort, RT, Gillum, RF, Hansson, PO, Ikram, MK, Kronmal, RA, Pablos, DL, Malyutina, So, Ibañez, AM, Mathiesen, EB, Meade, TW, Meyer, HE, Moons, KGM, Nordestgaard, BG, Psaty, BM, Garcia, JRQ, Ridker, PM, C Sans, Schwartz, JE, Selmer, RM, Shipley, MJ, Tong, TYN, van der Schouw, YT, Verschuren, WMM, Wareham, NJ, Achenbach, S, Aleksandrova, K, Amiano, P, San Sebastian, D, Amouyel, P, Andersson, J, Bakker, S, Da Providencia Costa, R, Beulens, J, Blaha, M, Bobak, M, Boer, J, Bonet, C, Bonnet, F, Boutron-Ruault, M, Braaten, T, Brenner, H, Brunner, F, Brunner, E, Brunström, M, Buring, J, Butterworth, A, Capkova, N, Cesana, G, Chrysohoou, C, Colorado-Yohar, S, Cook, N, Cooper, C, Dahm, C, Davidson, K, Dennison, E, Di Castelnuovo, A, Donfrancesco, C, Dörr, M, Doryńska, A, Eliasson, M, Engström, G, Ferrari, P, Ferrario, M, Ford, I, Fu, M, Gansevoort, R, Giampaoli, S, Gillum, R, Gómez de la Cámara, A, Grassi, G, Hansson, P, Huculeci, R, Hveem, K, Iacoviello, L, Ikram, M, Jørgensen, T, Joseph, B, Jousilahti, P, Wouter Jukema, J, Kaaks, R, Katzke, V, Kavousi, M, Kiechl, S, Klotsche, J, König, W, Kronmal, R, Kubinova, R, Kucharska-Newton, A, Läll, K, Lehmann, N, Leistner, D, Linneberg, A, Pablos, D, Lorenz, T, Lu, W, Luksiene, D, Lyngbakken, M, Magnussen, C, Malyutina, S, Ibañez, A, Masala, G, Mathiesen, E, Matsushita, K, Meade, T, Melander, O, Meyer, H, Moons, K, Moreno-Iribas, C, Muller, D, Münzel, T, Nikitin, Y, Nordestgaard, B, Omland, T, Onland, C, Overvad, K, Packard, C, Pająk, A, Palmieri, L, Panagiotakos, D, Panico, S, Perez-Cornago, A, Peters, A, Pietilä, A, Pikhart, H, Psaty, B, Quarti-Trevano, F, Garcia, J, Riboli, E, Ridker, P, Rodriguez, B, Rodriguez-Barranco, M, Rosengren, A, Roussel, R, Sacerdote, C, S, S, Sattar, N, Schiborn, C, Schmidt, B, Schöttker, B, Schulze, M, Schwartz, J, Selmer, R, Shea, S, Shipley, M, Sieri, S, Söderberg, S, Sofat, R, Tamosiunas, A, Thorand, B, Tillmann, T, Tjønneland, A, Tong, T, Trichopoulou, A, Tumino, R, Tunstall-Pedoe, H, Tybjaerg-Hansen, A, Tzoulaki, J, van der Heijden, A, van der Schouw, Y, Verschuren, W, Völzke, H, Waldeyer, C, Wareham, N, Weiderpass, E, Weidinger, F, Wild, P, Willeit, J, Willeit, P, Wilsgaard, T, Woodward, M, Zeller, T, Zhang, D, Zhou, B, Bakker, SJL, Da Providencia Costa, RB, Beulens, JWJ, Boer, JMA, Boutron-Ruault, MC, Brunner, EJ, Butterworth, AS, Cook, NR, Dahm, CC, Gansevoort, RT, Gillum, RF, Hansson, PO, Ikram, MK, Kronmal, RA, Pablos, DL, Malyutina, So, Ibañez, AM, Mathiesen, EB, Meade, TW, Meyer, HE, Moons, KGM, Nordestgaard, BG, Psaty, BM, Garcia, JRQ, Ridker, PM, C Sans, Schwartz, JE, Selmer, RM, Shipley, MJ, Tong, TYN, van der Schouw, YT, Verschuren, WMM, and Wareham, NJ
- Abstract
Aims: The aim of this study was to develop, validate, and illustrate an updated prediction model (SCORE2) to estimate 10-year fatal and non-fatal cardiovascular disease (CVD) risk in individuals without previous CVD or diabetes aged 40-69 years in Europe. Methods and results : We derived risk prediction models using individual-participant data from 45 cohorts in 13 countries (677 684 individuals, 30 121 CVD events). We used sex-specific and competing risk-adjusted models, including age, smoking status, systolic blood pressure, and total- and HDL-cholesterol. We defined four risk regions in Europe according to country-specific CVD mortality, recalibrating models to each region using expected incidences and risk factor distributions. Region-specific incidence was estimated using CVD mortality and incidence data on 10 776 466 individuals. For external validation, we analysed data from 25 additional cohorts in 15 European countries (1 133 181 individuals, 43 492 CVD events). After applying the derived risk prediction models to external validation cohorts, C-indices ranged from 0.67 (0.65-0.68) to 0.81 (0.76-0.86). Predicted CVD risk varied several-fold across European regions. For example, the estimated 10-year CVD risk for a 50-year-old smoker, with a systolic blood pressure of 140 mmHg, total cholesterol of 5.5 mmol/L, and HDL-cholesterol of 1.3 mmol/L, ranged from 5.9% for men in low-risk countries to 14.0% for men in very high-risk countries, and from 4.2% for women in low-risk countries to 13.7% for women in very high-risk countries. Conclusion : SCORE2-a new algorithm derived, calibrated, and validated to predict 10-year risk of first-onset CVD in European populations-enhances the identification of individuals at higher risk of developing CVD across Europe.
- Published
- 2021
30. Childhood determinants of adult ideal cardiovascular health: The Cardiovascular Risk in Young Finns Study: 32
- Author
-
Laitinen, T T, Pahkala, K, Viikari, J SA, Taittonen, L, Laitinen, T, Jokinen, E, Hutri-Kahonen, N, Raitakari, O T, Magnussen, C G, and Juonala, M
- Published
- 2013
31. Candida parapsilosis: Empyema or iatrogenic infection?
- Author
-
El-Daher, Nayef and Magnussen, C. Richard
- Subjects
Medicine ,Candidiasis -- Varieties ,Health ,Varieties - Abstract
Candida parapsilosis has been associated with fungemia, endocarditis, septic arthritis, and peritonitis in immunocompromised patients and with invasive procedures and prosthetic devices in immunocompetent patients. It has emerged as an [...]
- Published
- 2002
32. The role of pharmacotherapy in the prevention and treatment of paediatric metabolic syndrome – Implications for long-term health: Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni☆
- Author
-
Sabin, M. A., Magnussen, C. G., Juonala, M., Cowley, M. A., and Shield, J. P.H.
- Published
- 2012
- Full Text
- View/download PDF
33. (544) Patient-Reported Outcomes in Short-Time Follow-Up after Discharge of Patients with Advanced Heart Failure
- Author
-
Wagner, T., Zhou, L., Magnussen, C., Bernhardt, A., Reichenspurner, H., Kirchhof, P., and Grahn, H.
- Published
- 2023
- Full Text
- View/download PDF
34. Association of Low Birth Weight With Subclinical Cardiovascular Disease in Adulthood
- Author
-
Huynh, Q., primary, Venn, A., additional, Magnussen, C., additional, Yang, H., additional, Dwyer, T., additional, and Marwick, T., additional
- Published
- 2021
- Full Text
- View/download PDF
35. Prediction of Future Atherosclerosis From Young Adulthood
- Author
-
Huynh, Q., primary, Venn, A., additional, Magnussen, C., additional, Dwyer, T., additional, and Marwick, T., additional
- Published
- 2021
- Full Text
- View/download PDF
36. Predictive associations between alternative measures of childhood adiposity and adult cardio-metabolic health
- Author
-
Schmidt, M D, Dwyer, T, Magnussen, C G, and Venn, A J
- Published
- 2011
- Full Text
- View/download PDF
37. Childhood socioeconomic disadvantage and risk of fatty liver in adulthood:the cardiovascular risk in young Finns study
- Author
-
Laitinen, T. T. (Tomi T.), Vahtera, J. (Jussi), Pahkala, K. (Katja), Magnussen, C. G. (Costan G.), Nuotio, J. (Joel), Hutri-Kähönen, N. (Nina), Kivimäki, M. (Mika), Lehtimäki, T. (Terho), Jokinen, E. (Eero), Laitinen, T. (Tomi), Tossavainen, P. (Päivi), Pentti, J. (Jaana), Viikari, J. S. (Jorma S.A.), Juonala, M. (Markus), and Raitakari, O. T. (Olli T.)
- Abstract
Fatty liver is a preventable cause of liver failure, but early risk factors for adulthood fatty liver are poorly understood. We examined the association of childhood socioeconomic disadvantage with adulthood fatty liver and tested adulthood risk factors of fatty liver as possible mediators of this link. The study population comprised 2,042 participants aged 3‐18 years at baseline (1980) from the longitudinal Cardiovascular Risk in Young Finns Study. Follow‐up with repeated clinical examinations was 31 years. Childhood socioeconomic disadvantage was assessed using data from parents’ socioeconomic position and socioeconomic circumstances in participants’ residential neighborhoods, categorized as high versus low socioeconomic disadvantage. Fatty liver was determined by ultrasound during the last follow‐up (2011) at ages 34‐49 years. Childhood and adulthood risk factors, including metabolic biomarkers and lifestyle variables, were assessed in clinical examinations. A total of 18.9% of the participants had fatty liver in adulthood. High childhood socioeconomic disadvantage was associated with an increased risk of fatty liver (risk ratio [95% confidence interval], 1.42 [1.18‐1.70]; P = 0.0002). This association was robust to adjustment for age, sex, and childhood risk factors of fatty liver, including high body mass index, elevated insulin, and low birth weight (1.33 [1.09‐1.62]; P = 0.005). High childhood socioeconomic disadvantage was also associated with the development of risk factors of fatty liver in adulthood. Adulthood risk factors linking childhood socioeconomic disadvantage with fatty liver included waist circumference (proportion mediated of the total effect of childhood socioeconomic disadvantage, 45%), body mass index (40%), systolic blood pressure (29%), insulin (20%), physical activity (15%), triglycerides (14%), and red meat consumption (7%). Conclusion: Childhood socioeconomic disadvantage was associated with multiple risk factors of fatty liver and increased likelihood of fatty liver in adulthood.
- Published
- 2020
38. High-Sensitivity Cardiac Troponin I Levels and Prediction of Heart Failure : Results From the BiomarCaRE Consortium
- Author
-
Yan, I., Borschel, C. S., Neumann, J. T., Sprunker, N. A., Makarova, N., Kontto, J., Kuulasmaa, K., Salomaa, V., Magnussen, C., Iacoviello, L., Di Castelnuovo, A., Costanzo, S., Linneberg, A., Soderberg, S., Zeller, T., Ojeda-Echevarria, F. M., Blankenberg, S., and Westermann, D.
- Subjects
cardiovascular risk factors ,BiomarCaRE ,high-sensitivity cardiac troponin I ,N-terminal pro-B-type natriuretic peptide ,prediction of heart failure ,Kardiologi ,Cardiac and Cardiovascular Systems - Abstract
Objectives: The aims of this study were to characterize the association of high-sensitivity cardiac troponin I (hs-cTnI) with heart failure (HF), to determine its predictive value beyond classical cardiovascular risk factors (CVRFs) and N-terminal pro–B-type natriuretic peptide, and to derive a relevant cutoff for potential clinical application. Background: HF is an important contributor to the overall burden of cardiovascular disease. Early identification of individuals at risk could be beneficial for preventive therapies. Methods: Based on the Biomarker for Cardiovascular Risk Assessment in Europe consortium, we analyzed individual-level data from 4 prospective population-based cohort studies including 48,455 individuals. Participants with myocardial infarction, HF, and stroke at baseline were excluded. We investigated the value of adding hs-cTnI to CVRFs and N-terminal pro–B-type natriuretic peptide using Cox proportional hazards survival models and for prediction by calculating C-statistics and Brier score. Results: The median age of the study population was 51 years, and the median follow-up time for occurrence of HF was 6.61 years. Cox regression models adjusted for age, sex, and CVRFs revealed a significant association of hs-cTnI with incident HF (hazard ratio: 1.42 per log [ng/l] unit change [95% confidence interval: 1.31 to 1.53]). The best predictive value was achieved in the model with CVRFs (base model) and both biomarkers (C-index = 0.862; 95% confidence interval: 0.841 to 0.882). Optimal hs-cTnI cutoff values of 2.6 ng/l for women and 4.2 ng/l for men were derived for selecting individuals at risk. Conclusions: In this large dataset from the general population, hs-cTnI could show its independence for the prognosis of HF.
- Published
- 2020
- Full Text
- View/download PDF
39. Risk Of metabolic syndrome in adulthood attributable to childhood grip strength
- Author
-
Fraser, B, Blizzard, L, Schmidt, M, Dwyer, T, Venn, A, and Magnussen, C
- Published
- 2019
- Full Text
- View/download PDF
40. Young adults with a family history of cardio-metabolic disease have persisting and worsening health behaviours
- Author
-
Sahle, B, Bui, T, Magnussen, C, Cleland, V, Dwyer, T, Venn, A, and Gall, S
- Published
- 2019
41. Time spent watching television impacts on body mass index in youth with obesity, but only in those with shortest sleep duration
- Author
-
Golshevsky, DM, Magnussen, C, Juonala, M, Kao, K-T, Harcourt, BE, Sabin, MA, Golshevsky, DM, Magnussen, C, Juonala, M, Kao, K-T, Harcourt, BE, and Sabin, MA
- Abstract
AIM: To determine the interplay between sleep and sedentary behaviours on body mass index (BMI) in children with obesity. METHODS: Cross-sectional study of 343 children with obesity aged 4-17 years, from a tertiary care weight management clinic in Melbourne, Victoria, Australia. Multifaceted data relating to activity and sleep from child and parent questionnaires analysed with anthropometric data collected during routine clinical care. Associations between sleep duration and activity measures were examined via regression models with adjustment for potential confounders. RESULTS: Higher BMI was associated with more hours spent watching television (P = 0.04), as well as less reported enjoyment of physical activity (P = 0.005) and less time spent in organised sport activity (P = 0.005). Higher BMI was also associated with higher levels of obstructive sleep apnoea (P = 0.002). Less time in bed was associated with higher levels of BMI (P = 0.03) but analysis by sex revealed this association to only hold for males. In the whole group, a significant television and sleep interaction was seen, such that increasing television watching was associated with higher BMI, but only in those with shortest sleep duration. CONCLUSIONS: Both poor sleep and increasing screen time (including television viewing, smart-phone use, internet use or video-gaming) appear to impact BMI in children with obesity, with a particular detrimental effect of television viewing in those who sleep less. Efforts to improve sleep time and quality in children may minimise negative effects of screen time on increasing BMI and should be included in public health strategies to combat obesity in childhood.
- Published
- 2020
42. Childhood exposure to parental smoking and midlife cognitive function:the Young Finns Study
- Author
-
Rovio, S. P. (Suvi P.), Pihlman, J. (Jukka), Pahkala, K. (Katja), Juonala, M. (Markus), Magnussen, C. G. (Costan G.), Pitkänen, N. (Niina), Ahola-Olli, A. (Ari), Salo, P. (Pia), Kähönen, M. (Mika), Hutri-Kähönen, N. (Nina), Lehtimäki, T. (Terho), Jokinen, E. (Eero), Laitinen, T. (Tomi), Taittonen, L. (Leena), Tossavainen, P. (Päivi), Viikari, J. S. (Jorma S. A.), Raitakari, O. T. (Olli T.), Rovio, S. P. (Suvi P.), Pihlman, J. (Jukka), Pahkala, K. (Katja), Juonala, M. (Markus), Magnussen, C. G. (Costan G.), Pitkänen, N. (Niina), Ahola-Olli, A. (Ari), Salo, P. (Pia), Kähönen, M. (Mika), Hutri-Kähönen, N. (Nina), Lehtimäki, T. (Terho), Jokinen, E. (Eero), Laitinen, T. (Tomi), Taittonen, L. (Leena), Tossavainen, P. (Päivi), Viikari, J. S. (Jorma S. A.), and Raitakari, O. T. (Olli T.)
- Abstract
We studied whether exposure to parental smoking in childhood/adolescence is associated with midlife cognitive function, leveraging data from the Cardiovascular Risk in Young Finns Study. A population-based cohort of 3,596 children/adolescents aged 3–18 years was followed between 1980 and 2011. In 2011, cognitive testing was performed on 2,026 participants aged 34–49 years using computerized testing. Measures of secondhand smoke exposure in childhood/adolescence consisted of parental self-reports of smoking and participants’ serum cotinine levels. Participants were classified into 3 exposure groups: 1) no exposure (nonsmoking parents, cotinine <1.0 ng/mL); 2) hygienic parental smoking (1–2 smoking parents, cotinine <1.0 ng/mL); and 3) nonhygienic parental smoking (1–2 smoking parents, cotinine ≥1.0 ng/mL). Analyses adjusted for sex, age, family socioeconomic status, polygenic risk score for cognitive function, adolescent/adult smoking, blood pressure, and serum total cholesterol level. Compared with the nonexposed, participants exposed to nonhygienic parental smoking were at higher risk of poor (lowest quartile) midlife episodic memory and associative learning (relative risk (RR) = 1.38, 95% confidence interval (CI): 1.08, 1.75), and a weak association was found for short-term and spatial working memory (RR = 1.25, 95% CI: 0.98, 1.58). Associations for those exposed to hygienic parental smoking were nonsignificant (episodic memory and associative learning: RR = 1.19, 95% CI: 0.92, 1.54; short-term and spatial working memory: RR = 1.10, 95% CI: 0.85, 1.34). We conclude that avoiding childhood/adolescence secondhand smoke exposure promotes adulthood cognitive function.
- Published
- 2020
43. Childhood risk factors and carotid atherosclerotic plaque in adulthood:the cardiovascular risk in Young Finns Study
- Author
-
Koskinen, J. S. (Juhani S.), Kytö, V. (Ville), Juonala, M. (Markus), Viikari, J. S. (Jorma S. A.), Nevalainen, J. (Jaakko), Kähönen, M. (Mika), Lehtimäki, T. (Terho), Hutri-Kähönen, N. (Nina), Laitinen, T. (Tomi), Tossavainen, P. (Päivi), Jokinen, E. (Eero), Magnussen, C. G. (Costan G.), Raitakari, O. T. (Olli T.), Koskinen, J. S. (Juhani S.), Kytö, V. (Ville), Juonala, M. (Markus), Viikari, J. S. (Jorma S. A.), Nevalainen, J. (Jaakko), Kähönen, M. (Mika), Lehtimäki, T. (Terho), Hutri-Kähönen, N. (Nina), Laitinen, T. (Tomi), Tossavainen, P. (Päivi), Jokinen, E. (Eero), Magnussen, C. G. (Costan G.), and Raitakari, O. T. (Olli T.)
- Abstract
Background and aims: Carotid plaque is a specific sign of atherosclerosis and adults with carotid plaque are at increased risk for cardiovascular outcomes. Atherosclerosis has roots in childhood and pediatric guidelines provide cut-off values for cardiovascular risk factors. However, it is unknown whether these cut-offs predict adulthood advanced atherosclerosis. Methods: The Cardiovascular Risk in Young Finns Study is a follow-up of children that begun in 1980 when 2653 participants with data for the present analyses were aged 3—18 years. In 2001 and 2007 follow-ups, in addition to adulthood cardiovascular risk factors, carotid ultrasound data was collected. Long-term burden, as the area under the curve, was evaluated for childhood (6—18 years) risk factors. To study the associations of guideline-based cut-offs with carotid plaque, both childhood and adult risk factors were classified according to clinical practice guidelines. Results: Carotid plaque, defined as a focal structure of the arterial wall protruding into lumen <50% compared to adjacent intima-media thickness, was present in 88 (3.3%) participants. Relative risk for carotid plaque, when adjusted for age and sex, was 3.03 (95% CI, 1.76—5.21) for childhood dyslipidemia, 1.51 (95% CI, 0.99—2.32) for childhood elevated systolic blood pressure, and 1.93 (95% CI, 1.26—2.94) for childhood smoking. Childhood dyslipidemia and smoking remained independent predictors of carotid plaque in models additionally adjusted for adult risk factors and family history of coronary heart disease. Carotid plaque was present in less than 1% of adults with no childhood risk factors. Conclusions: Findings reinforce childhood prevention efforts and demonstrate the utility of guideline-based cut-offs in identifying children at increased risk for adulthood atherosclerosis.
- Published
- 2020
44. Intraoperative flurbiprofen alters the expression of PD-1, a molecule of immune checkpoint pathway, in patients undergoing elective thoracoscope resection of lung cancer: a randomized controlled trial
- Author
-
Magnussen C, Chai X, Xie L, Hu J, Shu S, Wang D, and Hu S
- Subjects
Oncology ,medicine.medical_specialty ,Thoracoscope ,business.industry ,Flurbiprofen ,medicine.disease ,Immune checkpoint ,law.invention ,Resection ,Text mining ,Randomized controlled trial ,law ,Internal medicine ,Medicine ,In patient ,business ,Lung cancer ,medicine.drug - Abstract
Background: This study aimed to determine the influence of intraoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) flurbiprofen on postoperative level of programmed death 1 (PD-1) in patients undergoing thoracoscope surgery. Methods: In this prospective double-blind trial, patients were randomized to receive intralipid (Control group, n=34, 0.1ml/kg, i.v.) or flurbiprofen axetil (Flurbiprofen group, n=34, 1mg/kg, i.v.) before the induction of anesthesia and 6 hours after the initial injection. PD-1 level on T-cell subsets, inflammation and immune markers in peripheral blood were examined before induction of anesthesia (T0), and after surgery (24 hours (T1), 72 hours (T2) and 1 week (T3)). A linear mixed model was used to examine whether the changes from baseline values (T0) between groups were different during our study. Results: The increases in the percentages of PD-1(+)CD8(+) T-cell observed at T1 and T2 in the control group were higher than in the flurbiprofen group (T1:12.91%±1.65% versus 7.86%±5.71%, P=0.031; T2:11.54%±1.54% versus 8.75%±1.73%, P=0.004) while no difference was observed at T1 and T2 between the groups in terms of change in percentages of PD-1(+)CD4(+) T-cell. Moreover, extensive changes in the percentages of lymphocytes subsets and the concentrations of inflammatory markers was observed at T1 and T2 after surgery, and flurbiprofen seemed to attenuate the most of changes. Conclusion: Perioperative administration of flurbiprofen attenuated postoperative PD-1 increase on CD8(+) T-cell up to 72 hours, but not after this time. The clinical relevance of changes with PD-1 to long-term outcome of surgery is still unknown. Trial registration: Chinese Clinical Trail Registry, ChiCTR-IPR-15006482 (date of registration June 2015) Keywords: Immune cells; Lung cancer; Flurbiprofen; Programmed death 1.
- Published
- 2018
- Full Text
- View/download PDF
45. An eating pattern characterised by skipped or delayed breakfast is associated with mood disorders among an Australian adult cohort
- Author
-
Wilson, J. E., primary, Blizzard, L., additional, Gall, S. L., additional, Magnussen, C. G., additional, Oddy, W. H., additional, Dwyer, T., additional, Sanderson, K., additional, Venn, A. J., additional, and Smith, K. J., additional
- Published
- 2019
- Full Text
- View/download PDF
46. P6310Risk predictors of cardiac allograft vasculopathy after heart transplantation: results from the United States Organ Procurement and Transplantation Network
- Author
-
Fluschnik, N, primary, Geelhoed, B, additional, Becher, P M, additional, Brunner, F J, additional, Schrage, B, additional, Knappe, D, additional, Bernhardt, A, additional, Blankenberg, S, additional, Kobashigawa, J, additional, Reichenspurner, H, additional, Schnabel, R B, additional, and Magnussen, C, additional
- Published
- 2019
- Full Text
- View/download PDF
47. P2505Cardiorespiratory fitness in childhood is an independent predictor of subclinical cardiovascular disease in adulthood: The Childhood Determinants of Adult Health Study
- Author
-
Huynh, Q, primary, Venn, A J, additional, Magnussen, C, additional, and Marwick, T H, additional
- Published
- 2019
- Full Text
- View/download PDF
48. P2449Different associations of cardiovascular risk factors with markers of subclinical myocardial disease over the life course
- Author
-
Huynh, Q, primary, Venn, A J, additional, Magnussen, C, additional, and Marwick, T H, additional
- Published
- 2019
- Full Text
- View/download PDF
49. 404Impact of cardiovascular risk factors for the development of cardiovascular disease: Results from MORGAM and BiomarCaRE consortia
- Author
-
Magnussen, C, primary
- Published
- 2019
- Full Text
- View/download PDF
50. Dilated cardiomyopathy: from epidemiologic to genetic phenotypes
- Author
-
Reichart, D., primary, Magnussen, C., additional, Zeller, T., additional, and Blankenberg, S., additional
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.